Lantheus (LNTH) Proxy filing summary

Executive summary

• Annual Meeting scheduled for April 30, 2026, with both in-person and virtual attendance options.

• 2025 marked by strategic acquisitions, divestiture of legacy business, and leadership transition.

• Focus on PET diagnostics, portfolio expansion, and operational excellence to drive growth.

• Nearly 7 million patient lives impacted in 2025, reflecting the company's clinical reach.

Voting matters and shareholder proposals

• Election of four Class II directors for three-year terms.

• Advisory vote on executive compensation (“say on pay”).

• Advisory vote on frequency of say-on-pay (Board recommends annual vote).

• Proposal to declassify the Board, moving to annual director elections by 2029.

• Approval of the Amended and Restated 2026 Equity Incentive Plan, increasing share reserve.

• Ratification of Deloitte as independent auditor for 2026.

Board of directors and corporate governance

• Board consists of 10 directors, 9 of whom are independent; strong gender and professional diversity.

• Board committees: Audit, Nominating and Corporate Governance, Talent and Compensation, Science and Technology.

• Annual board and committee self-assessments; recent focus on succession planning and committee refinement.

• Shareholder rights include proxy access, ability to call special meetings, and no poison pill.